AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pai, S. R.
Right arrow Articles by Murray, B. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pai, S. R.
Right arrow Articles by Murray, B. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2003, p. 2706-2709, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2706-2709.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vivo Efficacy of the Ketolide ABT-773 (Cethromycin) against Enterococci in a Mouse Peritonitis Model

Suresh R. Pai,1,2 Kavindra V. Singh,1,2 and Barbara E. Murray1,2,3*

Center for the Study of Emerging and Re-Emerging Pathogens,1 Division of Infectious Diseases, Department of Internal Medicine,2 Department of Microbiology and Molecular Genetics, The University of Texas Medical School, Houston, Texas 770303

Received 6 September 2002/ Returned for modification 17 February 2003/ Accepted 10 May 2003

Using six Enterococcus faecalis and five Enterococcus faecium strains, the ketolide ABT-773 (ABT), now known as cethromycin, was found to have in vivo efficacy against both erythromycin (ERY)-susceptible (Erys) and -intermediate (Eryi) enterococci (ABT 50% protective doses [PD50s], 0.5 to 4.1 and 10.3 to 16.2 mg/kg of body weight, respectively). Against four highly Ery-resistant (Eryr) strains for which ABT MICs were low, ABT showed much greater activity (PD50, 6.3 to 32.5 mg/kg) than ERY (PD50, >200 mg/kg) but was not protective for strains for which ABT MICs were high. In conclusion, ABT-773 showed in vivo efficacy and considerably greater activity than ERY in a mouse peritonitis model.

* Corresponding author. Mailing address: Center for the Study of Emerging and Re-Emerging Pathogens, University of Texas Medical School—Houston, 6431 Fannin, 1.737 JFB, Houston, TX 77030. Phone: (713) 500-6745. Fax: (713) 500-5495. E-mail: bem.asst{at}uth.tmc.edu.

Antimicrobial Agents and Chemotherapy, August 2003, p. 2706-2709, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2706-2709.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2003 by the American Society for Microbiology. All rights reserved.